Pfizer Finds 90.7% Efficacy in its Vaccine Dosage for Children Aged 5-11

Pfizer Finds 90.7% Efficacy in its Vaccine Dosage for Children Aged 5-11

No ratings yet.

In a Phase 2 and 3 study conducted in 2250 participants aged 5-11 years, vaccine efficacy for two doses of Pfizer-BioNTech COVID-19 Vaccine was 90.7% (measured at about 2.5 weeks). Dosing for these children was a third of the adult dosing. Vaccination in children with the Pfizer-BioNTech vaccine found to be comparably immunogenic (just as effective at activating the immune system for protection against COVID-19) as in adolescent/young adult populations.

Photo by Anna Shvets

Have comments, feedback, or suggestions?